Brokerages Expect Iqvia Holdings Inc (NYSE:IQV) Will Post Earnings of $1.05 Per Share

Equities analysts expect Iqvia Holdings Inc (NYSE:IQV) to report earnings of $1.05 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Iqvia’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $1.03. Iqvia reported earnings of $1.53 per share in the same quarter last year, which would indicate a negative year over year growth rate of 31.4%. The company is expected to report its next earnings results on Wednesday, July 22nd.

According to Zacks, analysts expect that Iqvia will report full-year earnings of $5.83 per share for the current financial year, with EPS estimates ranging from $5.29 to $6.05. For the next year, analysts forecast that the company will report earnings of $7.31 per share, with EPS estimates ranging from $6.60 to $7.83. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Iqvia.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Tuesday, April 28th. The medical research company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.02. Iqvia had a return on equity of 18.48% and a net margin of 1.93%. The business had revenue of $2.75 billion during the quarter, compared to analysts’ expectations of $2.74 billion. During the same period in the previous year, the firm posted $1.53 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis.

A number of brokerages have recently weighed in on IQV. Wells Fargo & Co lifted their price objective on Iqvia from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Stifel Nicolaus lifted their target price on Iqvia from $159.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Cfra decreased their target price on Iqvia from $185.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. SunTrust Banks lifted their target price on Iqvia from $128.00 to $172.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating and set a $170.00 target price for the company in a report on Tuesday, February 4th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and a consensus target price of $155.06.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sunbelt Securities Inc. purchased a new stake in Iqvia during the 4th quarter worth about $5,408,000. RMR Wealth Builders purchased a new stake in shares of Iqvia in the 4th quarter valued at about $27,000. Penserra Capital Management LLC lifted its holdings in shares of Iqvia by 57.5% in the 4th quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of Iqvia in the 4th quarter valued at about $32,000. Finally, Patriot Financial Group Insurance Agency LLC lifted its holdings in shares of Iqvia by 379.5% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 167 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Shares of NYSE IQV traded down $0.30 during trading on Monday, reaching $142.90. The stock had a trading volume of 682,879 shares, compared to its average volume of 1,204,950. Iqvia has a fifty-two week low of $81.79 and a fifty-two week high of $169.14. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.09 and a current ratio of 1.09. The business’s 50-day moving average price is $129.39 and its 200-day moving average price is $141.18. The company has a market cap of $27.35 billion, a P/E ratio of 129.91, a PEG ratio of 2.73 and a beta of 1.32.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.